The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer

Sima Singh; Arshid Numan; Balaji Maddiboyina; Saahil Arora; Yassine Riadi; Shadab Md; Nabil A. Alhakamy; Prashant Kesharwani

doi:10.1016/j.drudis.2021.03.011

The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer

Sima Singh
, Arshid Numan
, Balaji Maddiboyina
, Saahil Arora
, Yassine Riadi
, Shadab Md
, Nabil A. Alhakamy
, Prashant Kesharwani

Pharmaceutical Chemistry

Chandigarh University
Fudan University
NRK & KSR Gupta College of Pharmacy
King Abdulaziz University
Jamia Hamdard University

Research output: Contribution to journal › Review article › peer-review

106 Scopus citations

Abstract

Triple-negative breast cancers (TNBCs) form a heterogeneous group of breast carcinomas that lack expression of estrogen receptor, progesterone receptor and epidermal growth factor receptor 2. In the past decade, immune checkpoint inhibitors (ICIs) have revolutionized the arena of cancer immunotherapy. Early results are now accumulating from trials involving the treatment of TNBCs with radical ICIs therapies, including combinational therapies that include ICI technologies. In this review, we provide a broad overview of the progress of immunotherapy-based treatments and discuss future opportunities for their use in TNBC.

Original language	English
Pages (from-to)	1721-1727
Number of pages	7
Journal	Drug Discovery Today
Volume	26
Issue number	7
DOIs	https://doi.org/10.1016/j.drudis.2021.03.011
State	Published - Jul 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.drudis.2021.03.011

Cite this

@article{d1d56bc89ce748408a918e9386d9ddb7,

title = "The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer",

abstract = "Triple-negative breast cancers (TNBCs) form a heterogeneous group of breast carcinomas that lack expression of estrogen receptor, progesterone receptor and epidermal growth factor receptor 2. In the past decade, immune checkpoint inhibitors (ICIs) have revolutionized the arena of cancer immunotherapy. Early results are now accumulating from trials involving the treatment of TNBCs with radical ICIs therapies, including combinational therapies that include ICI technologies. In this review, we provide a broad overview of the progress of immunotherapy-based treatments and discuss future opportunities for their use in TNBC.",

author = "Sima Singh and Arshid Numan and Balaji Maddiboyina and Saahil Arora and Yassine Riadi and Shadab Md and Alhakamy, \{Nabil A.\} and Prashant Kesharwani",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",

year = "2021",

month = jul,

doi = "10.1016/j.drudis.2021.03.011",

language = "English",

volume = "26",

pages = "1721--1727",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Ltd",

number = "7",

}

TY - JOUR

T1 - The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer

AU - Singh, Sima

AU - Numan, Arshid

AU - Maddiboyina, Balaji

AU - Arora, Saahil

AU - Riadi, Yassine

AU - Md, Shadab

AU - Alhakamy, Nabil A.

AU - Kesharwani, Prashant

PY - 2021/7

Y1 - 2021/7

N2 - Triple-negative breast cancers (TNBCs) form a heterogeneous group of breast carcinomas that lack expression of estrogen receptor, progesterone receptor and epidermal growth factor receptor 2. In the past decade, immune checkpoint inhibitors (ICIs) have revolutionized the arena of cancer immunotherapy. Early results are now accumulating from trials involving the treatment of TNBCs with radical ICIs therapies, including combinational therapies that include ICI technologies. In this review, we provide a broad overview of the progress of immunotherapy-based treatments and discuss future opportunities for their use in TNBC.

AB - Triple-negative breast cancers (TNBCs) form a heterogeneous group of breast carcinomas that lack expression of estrogen receptor, progesterone receptor and epidermal growth factor receptor 2. In the past decade, immune checkpoint inhibitors (ICIs) have revolutionized the arena of cancer immunotherapy. Early results are now accumulating from trials involving the treatment of TNBCs with radical ICIs therapies, including combinational therapies that include ICI technologies. In this review, we provide a broad overview of the progress of immunotherapy-based treatments and discuss future opportunities for their use in TNBC.

UR - https://www.scopus.com/pages/publications/85103129881

U2 - 10.1016/j.drudis.2021.03.011

DO - 10.1016/j.drudis.2021.03.011

M3 - Review article

C2 - 33745879

AN - SCOPUS:85103129881

SN - 1359-6446

VL - 26

SP - 1721

EP - 1727

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 7

ER -

The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this